相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
M. A. Gouda et al.
ESMO OPEN (2023)
The coming decade in precision oncology: six riddles
Adam Wahida et al.
NATURE REVIEWS CANCER (2023)
Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies
Deepak Bhamidipati et al.
TRENDS IN CANCER (2023)
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
V Subbiah et al.
ANNALS OF ONCOLOGY (2022)
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Patrick Y. Wen et al.
LANCET ONCOLOGY (2022)
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
David Planchard et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
Yoon-Jung Kang et al.
SCIENTIFIC REPORTS (2022)
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
Vivek Subbiah et al.
NATURE MEDICINE (2022)
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Andrea Cercek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2022)
Impact of tissue-agnostic approvals for patients with sarcoma
Roberto Carmagnani Pestana et al.
TRENDS IN CANCER (2022)
Tumor Mutation Burden and Cancer Treatment
Michael J. Fusco et al.
JAMA ONCOLOGY (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A. Ascierto et al.
CLINICAL CANCER RESEARCH (2021)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.
Birgit Geoerger et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians
V. Subbiah et al.
ANNALS OF ONCOLOGY (2020)
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K. S. Salama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Histology-agnostic drug development - considering issues beyond the tissue
Roberto Carmagnani Pestana et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Five- year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma
Caroline Robert et al.
EUROPEAN JOURNAL OF CANCER (2019)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting Alterations in the RAF-MEK Pathway
Rona Yaeger et al.
CANCER DISCOVERY (2019)
Tumor mutation burden: from comprehensive mutational screening to the clinic
Francesca Galuppini et al.
CANCER CELL INTERNATIONAL (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Matthew Dankner et al.
ONCOGENE (2018)
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study
Eli L. Diamond et al.
JAMA ONCOLOGY (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
G. A. McArthur et al.
ANNALS OF ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Cancer immunotherapy: Historical Perspective of a Clinical Revolution and emerging Preclinical Animal Models
William K. Decker et al.
FRONTIERS IN IMMUNOLOGY (2017)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P. B. Chapman et al.
ANNALS OF ONCOLOGY (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
The development of a potent, KDRNEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers
B. Brandhuber et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer
YingYing Qian et al.
MOLECULAR CANCER (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Justin F. Gainor et al.
ONCOLOGIST (2013)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Targeting RET Receptor Tyrosine Kinase Activation in Cancer
John E. Phay et al.
CLINICAL CANCER RESEARCH (2010)
Cancer patients without a known primary: Incidence and survival trends in Sweden 1960-2007
Margareta Randen et al.
ACTA ONCOLOGICA (2009)
A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation
Sylvie Laquerre et al.
MOLECULAR CANCER THERAPEUTICS (2009)
New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors
Sandrine Faivre et al.
SEMINARS IN ONCOLOGY (2006)
RET tyrosine kinase signaling in development and cancer
E Arighi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
RET and NTRK1 proto-oncogenes in human diseases
L Albert et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
The RET proto-oncogene in human cancers
SM Jhiang
ONCOGENE (2000)
分享论文
